Kornimate/medical-research-clean huggingface dataset:
β-glucans and the metabolic syndrome - a human intervention study under best

Conditions: Healthy

Summary: the aim of this study is to investigate the potential disease preventive effects of β-glucans from oat and barley.

objective: the primary aim is to examine whether consumption of oat and two different barley β-glucans exhibits hypocholesterolemic effects and to understand the underlying mechanisms. secondary aims are to investigate whether there are also effects on blood pressure, appetite regulation, insulin sensitivity, hemostasis, low-grade inflammation and the metabolic profile of different biological materials. intervention: in each of the 4 intervention periods the participants drink a milk drink together with their three main meals for 21 days. this way they consume 5g β-glucan/d form either oat or barley in the three treatment periods, otherwise they maintain their habitual diet. they are not, however, allowed to eat any oat- or barley-containing products during the trial. at the beginning and at the end of each intervention period the participants' blood pressure is measured and a fasting blood sample is drawn. further they collect feces for 72 hours and urine for 24 hours before and at the end of each intervention period. before and at the end of each intervention period a 4-hour meal test is undertaken to measure their subject appetite sensation. here at first a fasting blood samples drawn and thereafter the milk drink is served. appetite sensation is assessed every 30 min for 4 hours. also blood samples are drawn at 2 hours and 4 hours at the meal tests which takes place before each intervention period. at the subsequent "ad libitum" lunch meal the food intake is measured and then a final appetite registration is made. furthermore participants make 4-d food records before and at the end of each intervention period.

Eligibility criteria:
inclusion criteria: * normal weight or moderately overweight (bmi 18.5-30 kg/m²) exclusion criteria: * chronic diseases (e.g. diabetes, cardiovascular disease) * elevated blood pressure * hyperlipidemia * consumption of dietary supplements during or 2 month prior to start of study (including vitamin tablets) * consumption of oat and barley products from january 1st until the end of study * smoking * excess physical activity (\> 8h/week) * medicine use (not included contraceptives or occasional pain killer consumption) * pregnancy * breast feeding

Keywords: β-glucan cholesterol bile acids blood glucose appetite
nexavar as first targeted therapy in patients with advanced renal cell carcinoma

Conditions: Carcinoma, Renal Cell

Summary: this is an observational study which will investigate the use of nexavar as first targeted therapy in patients with advanced renal cell carcinoma.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of advanced renal cell carcinoma (rcc) for whom the decision has been taken by the investigator to prescribe nexavar. * patients who failed cytokine therapy or who are not suitable for cytokines for whom nexavar is the first targeted drug treatment. exclusion criteria: * prior targeted therapy for rcc * contraindications of nexavar described in the summary of product characteristics (spc).

Keywords: renal cell carcinoma, first targeted therapy, observational study
impact of a self-exclusion procedure optimized by an extension of the suspension of commercial solicitations

Conditions: Gambling Disorder

Summary: considering that self-exclusion from gambling on a particular website is an intervention for and by individuals who have developed a gambling disorder, it is currently exclusively a behavioural intervention in the sense that it prevents the behaviour resumption of commercial solicitations only in the period when gambling is not accessible in the corresponding website , through voluntary self-exclusion (where the gambler prevents himself or herself from gambling), does not appear to be sufficient to prevent relapse. early commercial solicitations, in the immediate intercourse after the end of the self-exlcusion period may precipitate relapse in gamblers whose behaviour change is by definition recent, and who have only received a behavioural measure. the investigators hypothesize an improved efficacy as measured by reduced gambling after a self-exclusion optimized by a period of suspension of commercial solicitations extended to 9 months, compared to self-exclusion with the standard procedure. gamblers will be randomized according to an a priori randomization list.

this is a study evaluating the impact of pmu's implementation of an optimized self-exclusion procedure by extending the suspension of commercial solicitations for a total of 9 months, the self-exclusion being referred to as a non-medical "responsible gambling" tool, compared to the standard procedure. the self-excluded gamblers will be randomized according to an a priori randomization list, and will receive either the optimized self-exclusion procedure a or the standard self-exclusion procedure b. the study consists of a comparison between two groups a and b. the study involves non-medical gambling and socio-demographic data, routinely recorded in a regulatory manner with a permanent cnil authorization pmu.

Eligibility criteria:
inclusion criteria: * 18 years or older * self-excluder during the recruitment period * online sports betting * poker and horse racing player * account opened for at least 4 weeks * self-exclusion for 3 months or less (minimum 3 days). exclusion criteria: * player who has objected to the use of his collected data when opening his account. * it's not the first self-exclusion of the inclusion period.
genetic epidemiology of chd risk factors in blacks

Conditions: Cardiovascular Diseases; Heart Diseases; Coronary Disease

Summary: to determine the genetic epidemiology of coronary heart disease (chd) risk factors in blacks.

design narrative: the study used two well defined african populations from nigeria to determine the contribution of 14 polymorphic genes involved in lipid metabolism in determining quantitative lipoprotein-lipid and apolipoprotein levels as these are major risk factors for coronary heart disease. the study also investigated how differences in life styles and dietary habits modulate the genetic contribution of these quantitative risk factors. phenotypes in the gene products of apos a-iv, c-ii, d, h, j and (a) were determined by ief and sds/immunoblotting. genotypes at the b,e, ai-ciii- aiv cluster, lipoprotein lipase, hepatic lipase, ldl-receptor, and cholesterol ester transfer protein were determined by polymerase chain reaction protocols. the quantitative levels of total cholesterol, hdl-cholesterol and its subfractions, hdl2- and hdl3-cholesterol, triglycerides and lp(a) were used in the genetic analyses. estimates of the effect of alleles at each of the candidate loci on quantitative lipoprotein-lipid levels employed the measured genotype approach. the effect of multisite haplotypes for rflp at various loci, where applicable, was also estimated using the same method. the interaction of alleles at various independent loci in determining quantitative lipoprotein-lipid and apolipoprotein levels was estimated. in addition to the measurements of environmental effects, measurements were also made of the genotype-environmental interaction in determining quantitative risk factor traits. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
prognostic value of pre-therapy 18f-fdg pet/ct for the outcome of 18 fdg pet-guided sib-imrt in patients with head and neck cancer

Conditions: Head and Neck Cancer

Summary: head and neck cancer is the fifth most common cancer and represents 5% in the world. selecting patients for the most appropriate treatment remains difficult. approximately 60-65% of patients undergo surgery followed or not by radiotherapy. patients with early stage disease (i-ii) are treated with one treatment modality (surgery or radiotherapy), while patients with more advanced stage disease (iii-iv) receive multimodal treatment (surgery together with associated radiotherapy or less to chemotherapy). pet/ct plays a fundamental role in the management of head and neck cancer patients. this investigation is indicated for staging, especially in patients with disease in advanced stages, for evaluating the response to therapy and for looking for recurrences as it is more accurate in distinguishing scar tissue from neoplasm. the objective of this retrospective study is to evaluate the prognostic value of pet/ct in predicting the outcome of patients undergoing slb-imrt/intensity modulated radiotherapy). the study proposed here involves the retrospective recruitment of patients who have performed a pet/ct investigation with 18f-fdg (fluorodeoxyglucose) at the u.o. of hsr nuclear medicine in the staging and treatment planning phase, between 2005 and 2011. the inclusion condition of the patients was their pet/ct evaluation (planning and treatment) using the "dste" pet/ct system installed at the u.o. of nuclear medicine hsr on which, in the presence of homogeneous lesions. a particular correction technique is applicable, developed and validated previously by the research group, which allows possible metabolic markers to be extracted from the lesions in a quantitatively accurate way.


Eligibility criteria:
inclusion criteria: * patients suffering from head and neck cancer; * patients who underwent pet-ct with 18f-fdg. exclusion criteria: * patients \<18 years
diagnostic suspicion of primitive syndrome sjögren's : brest cohort

Conditions: Primary Sjögren's Syndrome (pSS)

Summary: this study aims to evaluate the diagnosis performance of several item used for the classification, the diagnosis and the prognostic of pss (primary sjogren syndrome)


Eligibility criteria:
inclusion criteria: * patients with suspected pss underwent a standardised evaluation exclusion criteria: * opposition of patient
heart smart: a virtual self-management program for homebound people with heart failure

Conditions: Heart Failure

Summary: the purpose of this capstone project is to pilot heart smart, a virtual group program to improve self-efficacy for self-management skills for homebound people with heart failure.

the purpose of this capstone project is to pilot heart smart, a virtual group program to improve self-efficacy for self-management skills for homebound people with heart failure. heart smart will provide synchronous virtual group education to homebound people with heart failure receiving services from penn medicine at home. the primary clinical goal is to improve self-efficacy for heart failure self-management and improve their knowledge of heart failure self-management strategies. secondary outcomes will explore the feasibility of the program by exploring technology, adherence and satisfaction with the program.

Eligibility criteria:
inclusion criteria: * diagnosis of heart failure * receiving home health care from penn medicine at home at time of screening. * technology capabilities to participate in the program (laptop or tablet with a camera, internet access). * able to read and write in english. * cognitive ability to participate in the program if the participant is able to score12/15 on the montreal cognitive assessment (moca) 5 minute phone test. exclusion criteria: * hearing impairment that impacts communication. * previous experience receiving occupational therapy services from the principal investigator.

Keywords: heart failure telehealth occupational therapy self-management
subjective/psychomotor/ effects of combined alcohol & nitrous oxide - 16

Conditions: Opioid-Related Disorders; Substance-Related Disorders

Summary: the purpose of this study is to examine the subjective, psychomotor, and reinforcing effects of combined alcohol and nitrous oxide intake in healthy volunteers.


Eligibility criteria:
please contact site for information.

Keywords: nitrous oxide inhalant ethanol subjective effects psychomotor effects healthy volunteer
burnout vs resilience among healthcare workers after the recent aggression in lebanon

Conditions: Burnout; Resilience

Summary: the purpose of this study is to assess the extent of burnout and the prevalence of resilience traits among healthcare workers in lebanon, specifically after the recent israeli aggression. this study will also explore factors related to burnout and resilience, as well as the relationship between resilience and mental well-being.


Eligibility criteria:
inclusion criteria: * healthcare workers currently working in lebanon including physicians, nurses, and other allied health workers (physiotherapists, psychologists, radiology technicians, occupational therapist, midwives, paramedics...). * students/interns training in these professions are also included. exclusion criteria: * non-healthcare staff * healthcare workers who stopped working during war
cd7 car t-cell therapy for r/r t-cell lymphomas

Conditions: T-Cell Non-Hodgkin Lymphoma; T-cell Lymphoma (PTCL and CTCL)

Summary: this is a multi-center, open-label, non-randomized, single-arm clinical trial. refractory/relapse t-nhl patients are treated with autologous and allogeneic cd7 car t-cell therapy. the primary objective is to prospectively evaluate the safety of cd7 car t cell bridging to hsct in the treatment of r/r t-nhl. the primary endpoint is the type and incidence of dose limiting toxicity (dlt) within 21 days after cd7 car-t cell infusion. a total of 36 subjects is estimated to be enrolled.


Eligibility criteria:
inclusion criteria (patients who met all the inclusion criteria were eligible for enrolment): * relapsed or refractory cd7-positive t-cell lymphomas that were treated with with standard chemotherapy, with poor prognosis from currently available treatments at and no available treatment options (e.g., hsct or chemotherapy); * male or female, age 14-70; * eastern cooperative oncology group (ecog) physical status score 0-2; * life expectancy is at least 60 days; * subjects should be capable of understanding and signing the informed consent form prior to any screening procedures. subjects are willing to follow the study visit schedule and associated study procedures as specified in the protocol. candidates between the ages of 19-70 years old will need to be sufficiently aware of and capable of signing the informed consent form; underage candidates between the ages of 14-18 years old will need to be sufficiently aware of the informed consent form and their legal guardian will also need to sign the informed consent form separately. exclusion criteria (patients who fulfil any of the following criteria may not be enrolled): * patients with history of allogeneic hsct but pbmnc is not available from prior- transplant donor for preparation of car t cells and peripheral blood tumour load \>30%; patients without history of allogeneic hsct and peripheral blood tumour load \>30%; * intracranial hypertension or cerebral impaired consciousness; * symptomatic heart failure or severe arrhythmia; * symptoms of severe respiratory failure; * with other types of malignancy; * diffuse intravascular coagulation; * serum creatinine and/or urea nitrogen ≥ 1.5 times the normal value; * with sepsis or other uncontrollable infection; * suffering from uncontrollable diabetes mellitus; * severe mental disorders; * have significant intracranial lesions on cranial mri; * organ transplantation (excluding haematopoietic stem cell transplantation) history; * female patients (patients of childbearing potential) with positive blood hcg test; * hepatitis (including hepatitis b and c) and positive screening for aids and syphilis.
influence of cromones on eucapnic hyperventilation (evh)-test in young (elite) athletes who tested positive for eib.

Conditions: Exercise-Induced Bronchoconstriction

Summary: this is a randomized, double-blinded, placebo-controlled trial of nebulized sodium cromoglycate (scg) (lomudal®) versus nacl0.9% in athletes (11-18 year) with exercise-induced bronchoconstriction (eib).

screening and diagnosing eib (studied by investigators in wp1 (s59778) and wp2 (s61602) of granted fwo-tbm project (t001417n)) in young athletes would only be useful if a safe and effective treatment is available. sodium cromoglycate (scg) has a very nice safety profile but is less effective when compared to inhaled corticosteroids in asthma patients. however, scg has been shown to be especially effective in exercise-induced asthma and to reduce metabolite secretion in athletes due to hyperpnoea. although commercial interest in the drug has fainted, from a clinical point of view, it remains the ideal candidate to be used in adolescents with features of eib at risk to develop asthma in whom today no treatment would be initiated. this clinical trial (s63147), which is wp3 of the fwo-tbm project, is a randomized double-blinded trial with subjects who tested positive for the diagnosis of eib in either wp1 or wp2. subjects who gave assent and whose parents gave consent will be randomized (1/1) in a double-blinded trial to receive either (arm 1) sodium cromoglycate (scg) (lomudal®) or (arm 2) placebo, both 4x1 ampulla (2 ml) in aerosol daily, during 6 months. during the previous trials, several tests were already performed. if subjects want to participate in this trial and the previous tests were more than 1 month ago, some tests will be repeated as a baseline: questionnaires, spirometry (with reversibility test) and evh-test. after 3 months, regular intake as well as potential side effects will be evaluated. after 6 months, in addition to questionnaires, clinical examination and spirometry with reversibility test, the evh-test will be repeated. subjects will also be offered the possibility to repeat (as they did for wp1 and wp2) a blood and sputum sampling at 6 months. afterwards, subjects will have the option to continue open-label treatment for 6 months. the investigators want to investigate the influence of scg on evh-test in young athletes who tested positive for eib.

Eligibility criteria:
inclusion criteria: * diagnosis of exercise-induced-bronchoconstriction (eib) based on positive evh-test in wp1 (s59778) or wp2 (s61602) * bmi between 5th and \<85th percentile for age and gender exclusion criteria: * clinically diagnosed asthma * baseline lung function: * fev1%: ≤80% predicted fev1% * tiffeneau: fev1/fvc% \< 85% * salbutamol-induced fev1 reversibility ≥ 12% * any disorder, which in the investigator's opinion might jeopardize participant's safety or compliance with the protocol * smoker * participation in other study related to imp * if applicable: female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method

Keywords: athletes sodium cromoglycate cromones lomudal
effects of pentoxifylline and vitamin e on pregnancy rate in infertile women treated by icsi:

Conditions: Infertility, Female

Summary: our findings will provide preliminary clinical evidence to suggest the new experimental treatment approaches, toward female factor infertility treatment with pentoxyfylline.

this randomized clinical trial will be conducted on 140 infertile patients. the study is approved by the ethical committee of benha obstetrics and gynecology department and will be initiated after achieving written consents of the participants. the study will include infertile patients under 39 years of age without a previous history of icsi cycle. exclusion criteria will be hypothalamic amenorrhea, drug reactions or complications, endometriosis and fibroids. patients will be randomly divided into two equal groups. computer generated random number table will be used for randomization. group assignments will be placed in sealed opaque sequentially numbered envelopes. for each participant a questionnaire will be filled by the researchers. the questionnaire contained questions about age, duration of infertility, the type and cause of infertility. data will be collected from questionnaires, clinical, laboratory notes and ultrasound reports. endometrial thickness will be measured on the day of the hcg prescription in both groups by one of the two attending physicians. chemical pregnancy will be detected by serum beta-hcg analysis 14 days after embryo transfer and transvaginal ultrasound scan will be scheduled 2 weeks later to confirm the diagnosis of clinical pregnancy. the intervention group will receive pentoxifylline (trental s.r.) 400 mg/bd plus vit e (pharco) 400 mg/bd 2 cycles before starting icsi cycle and the medication will be continued until the beta-hcg becomes positive or the cycle is cancelled. the comparison group will not receive the above drugs. the main outcome measure will be clinical pregnancy rate. sample size calculation sample size was calculated using pass® version 11 program, setting the type-1 error (α) at 0.05 and the power (1-β) at 0.8. results from a previous study (ashraf alesyan, 2009) showed that the incidence of pregnancy rate among ttt group was 57.1% while for control group it was 39.2%, with an effect size of 12%. calculation according to these values produced a minimal sample size of 131 cases in each group. results results will be statistically analyzed.

Eligibility criteria:
inclusion criteria: * infertile female patients under 39 years exclusion criteria: * hypothalamic amenorrhea * drug reactions or complications * endometrioses * fibroids

Keywords: assisted reproductive techniques
validation of a novel cerebellar-striatal satiety circuit in humans

Conditions: Appetitive Behavior; Obesity

Summary: this study uses a noninvasive technique called transcranial magnetic stimulation (tms) to study satiety in healthy individuals. tms is a noninvasive way of stimulating the brain, using a magnetic field to change activity in the brain. the magnetic field is produced by a coil that is held next to the scalp. in this study, the investigators will be stimulating the brain to learn more about the role of the cerebellum in satiety.

the purpose of this study is to conduct a circuit manipulation experiment to test the hypothesis that targeting the cerebellum can alter activity in response to food cues to advance the understanding of the involvement of the cerebellar-striatal circuit in feeding behavior. participants will undergo an initial screening session to complete informed consent and undergo baseline assessments including physical activity and food craving. participants will additionally undergo an mri scan that includes structural and resting-state functional magnetic resonance imaging (rsfmri). these rsfmri imagines will be used to isolate individual resting state networks for targeting of rtms modulation. participants will then complete two separate testing sessions involving mri imaging and food intake assessments before and after rtms. one visit will involve consumption of a filling meal; the other visit will be completed following an overnight fast.

Eligibility criteria:
inclusion criteria: * healthy individuals aged 18 to 65 * bmi of 20-35.0 kg/m2 * normal or corrected-to-normal vision * good general health * ability to understand and willingness to sign written informed consent document exclusion criteria: * current and/or past medical conditions * current and/or past eating disorder * on a restricted diet and/or taking weight loss medication(s) * history of bariatric surgery * weight fluctuation \>3% in past 3 months * recent history of illicit recreational drug abuse * current nicotine use * intellectual disability * conditions that might result in increased risks of side effects or complications from tms or mri